TW202111723A - Apparatus and method for processing of a prescription - Google Patents
Apparatus and method for processing of a prescription Download PDFInfo
- Publication number
- TW202111723A TW202111723A TW108132337A TW108132337A TW202111723A TW 202111723 A TW202111723 A TW 202111723A TW 108132337 A TW108132337 A TW 108132337A TW 108132337 A TW108132337 A TW 108132337A TW 202111723 A TW202111723 A TW 202111723A
- Authority
- TW
- Taiwan
- Prior art keywords
- code
- drug
- threshold
- weights
- weight
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000012545 processing Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 202
- 238000003745 diagnosis Methods 0.000 claims abstract description 29
- 238000004891 communication Methods 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims description 174
- 230000004044 response Effects 0.000 claims description 5
- 208000036647 Medication errors Diseases 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 43
- 208000007530 Essential hypertension Diseases 0.000 description 34
- 239000002220 antihypertensive agent Substances 0.000 description 33
- 229940030600 antihypertensive agent Drugs 0.000 description 33
- 206010020772 Hypertension Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
- 229960003105 metformin Drugs 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 230000005802 health problem Effects 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010007859 Lisinopril Proteins 0.000 description 4
- 201000008481 benign essential hypertension Diseases 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 4
- 229960002394 lisinopril Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Images
Landscapes
- Medical Treatment And Welfare Office Work (AREA)
- Medicines Containing Plant Substances (AREA)
- Control And Other Processes For Unpacking Of Materials (AREA)
Abstract
Description
本發明係關於一種用於處理處方之裝置及方法。更特定言之,本發明係關於一種用於偵測藥物錯誤之裝置及方法。The present invention relates to a device and method for processing prescriptions. More specifically, the present invention relates to a device and method for detecting drug errors.
常見之藥物錯誤危害患者之健康或甚至造成患者最終出現危及生命之病症,而且極大且不知不覺地增加醫療支出。若在開處方時或在由不同專家開處之藥物之間的交叉反應之情況下,醫師未考慮患者之病況,則將發生此情況。Common medication mistakes endanger the health of patients or even cause patients to eventually develop life-threatening illnesses, and greatly and unknowingly increase medical expenses. This will happen if the physician does not consider the patient’s condition at the time of prescription or in the case of cross-reactions between drugs prescribed by different experts.
統計資料報導在美國每年接近100,000名個體死於可預防的醫療錯誤,大部分為藥物錯誤。另外,研究亦報導39%藥物錯誤發生在開處方期間;12%發生在處方轉錄/登打;11%發生在藥房調配,及39%發生在交付或實際使用上。僅2%藥物錯誤在藥物投與過程中的一些時刻被攔截。鑒於上文,為了偵測藥物錯誤,需要提供一種用於處理處方之裝置及方法以幫助醫師及藥劑師判定處方之適當性。Statistics report that nearly 100,000 individuals die from preventable medical errors each year in the United States, most of which are drug errors. In addition, the study also reported that 39% of medication errors occurred during the prescription; 12% occurred in prescription transcription/entry; 11% occurred in pharmacy compounding, and 39% occurred in delivery or actual use. Only 2% of drug errors were intercepted at some point in the drug administration process. In view of the above, in order to detect drug errors, it is necessary to provide a device and method for processing prescriptions to help physicians and pharmacists determine the appropriateness of prescriptions.
為改良偵測藥物錯誤之效率,吾等使用用於辨識診斷-藥物相關性及藥物-藥物相關性之資料採擷技術之集合以便開發處理處方之機率模型。然而,可基於新適應症、標籤外使用(off-label uses)或醫生之經驗的一些藥物可偵測為藥物錯誤,且將發生頻繁警告或通知。此外,一些錯誤的診斷-藥物相關性(偽相關性)可發生在資料採擷期間。舉例而言,抗高血壓藥劑可相對於高血壓及糖尿病兩者具有高相關性,此係因為糖尿病患者經常患有高血壓。In order to improve the efficiency of detecting drug errors, we use a collection of data acquisition techniques for identifying diagnosis-drug correlation and drug-drug correlation in order to develop a probability model for processing prescriptions. However, some drugs that can be based on new indications, off-label uses, or doctor’s experience can be detected as drug errors, and frequent warnings or notifications will occur. In addition, some erroneous diagnosis-drug correlations (pseudo correlations) can occur during data collection. For example, antihypertensive agents may have a high correlation with both hypertension and diabetes, because diabetic patients often suffer from hypertension.
在一個態樣中,根據一些實施例,裝置包含至少一個非暫時性電腦可讀媒體及至少一個處理器。至少一個非暫時性電腦可讀媒體具有儲存於其中之電腦可執行指令。至少一個處理器耦接至至少一個非暫時性電腦可讀媒體。至少一個非暫時性電腦可讀媒體及電腦可執行指令與至少一個處理器經組態以使得裝置執行:接收第一代碼集;輸出第一代碼集之一或多個藥物代碼;接收回應於所輸出藥物代碼之第一訊息;以及更新與至少一個處理器通訊之資料庫中之與所輸出藥物代碼相關聯的第一權重及第二權重。第一代碼集包含至少一個診斷代碼及至少一個藥物分類。In one aspect, according to some embodiments, the device includes at least one non-transitory computer-readable medium and at least one processor. At least one non-transitory computer-readable medium has computer-executable instructions stored therein. At least one processor is coupled to at least one non-transitory computer-readable medium. At least one non-transitory computer-readable medium and computer-executable instructions and at least one processor are configured to cause the device to execute: receive a first code set; output one or more drug codes in the first code set; Output the first message of the medicine code; and update the first weight and the second weight associated with the output medicine code in the database in communication with the at least one processor. The first code set includes at least one diagnostic code and at least one drug classification.
在一個態樣中,根據一些實施例,裝置包含至少一個非暫時性電腦可讀媒體及至少一個處理器。至少一個非暫時性電腦可讀媒體具有儲存於其中之電腦可執行指令。至少一個處理器耦接至至少一個非暫時性電腦可讀媒體。至少一個非暫時性電腦可讀媒體及電腦可執行指令與至少一個處理器經組態以使得裝置執行:接收第一代碼集;將第一代碼集之診斷代碼及藥物代碼輸出至與至少一個處理器通訊之資料庫,其中;接收與來自資料庫之第一代碼集之診斷代碼及藥物代碼相關聯之第一權重及第二權重;以及對於第一代碼集之各藥物代碼,用至少一個處理器儲存具有最大值之第一權重。第一代碼集包含至少一個診斷代碼及至少一個藥物分類。資料庫包括在診斷代碼與藥物代碼之間的第一權重(QDM )及在藥物代碼與另一藥物代碼之間的第二權重(QMM ),且第一權重及第二權重大於零。In one aspect, according to some embodiments, the device includes at least one non-transitory computer-readable medium and at least one processor. At least one non-transitory computer-readable medium has computer-executable instructions stored therein. At least one processor is coupled to at least one non-transitory computer-readable medium. At least one non-transitory computer-readable medium and computer-executable instructions and at least one processor are configured to cause the device to execute: receive a first code set; output the diagnostic code and medication code of the first code set to and at least one process A database of device communication, wherein: receiving the first weight and the second weight associated with the diagnostic code and drug code of the first code set from the database; and processing each drug code in the first code set with at least one The device stores the first weight with the largest value. The first code set includes at least one diagnostic code and at least one drug classification. The database includes a first weight (Q DM ) between a diagnostic code and a medicine code and a second weight (Q MM ) between a medicine code and another medicine code, and the first weight and the second weight are greater than zero.
在一個態樣中,根據一些實施例,裝置包含至少一個非暫時性電腦可讀媒體及至少一個處理器。至少一個非暫時性電腦可讀媒體具有儲存於其中之電腦可執行指令。至少一個處理器耦接至至少一個非暫時性電腦可讀媒體。至少一個非暫時性電腦可讀媒體及電腦可執行指令與至少一個處理器經組態以使得裝置執行:接收在來自與至少一個處理器通訊之資料庫的診斷代碼與藥物代碼之間的第一權重;以及對於各藥物代碼,將具有最大值之第一權重輸出至與至少一個處理器通訊之資料庫。In one aspect, according to some embodiments, the device includes at least one non-transitory computer-readable medium and at least one processor. At least one non-transitory computer-readable medium has computer-executable instructions stored therein. At least one processor is coupled to at least one non-transitory computer-readable medium. At least one non-transitory computer-readable medium and computer-executable instructions and at least one processor are configured to cause the device to execute: receiving the first data between the diagnostic code and the medication code from a database in communication with the at least one processor Weight; and for each drug code, output the first weight with the maximum value to the database communicating with at least one processor.
在一個態樣中,根據一些實施例,用於處理處方之方法包含:接收第一代碼集;輸出第一代碼集之一或多個藥物代碼;接收回應於所輸出藥物代碼之第一訊息;以及更新資料庫中之與所輸出藥物代碼相關聯的第一權重及第二權重。第一代碼集包含至少一個診斷代碼及至少一個藥物分類。In one aspect, according to some embodiments, a method for processing a prescription includes: receiving a first code set; outputting one or more medicine codes of the first code set; receiving a first message in response to the output medicine code; And update the first weight and the second weight associated with the output drug code in the database. The first code set includes at least one diagnostic code and at least one drug classification.
在一個態樣中,根據一些實施例,用於處理處方之方法包含:接收第一代碼集;將第一代碼集之診斷代碼及藥物代碼輸出至資料庫;接收與來自資料庫之第一代碼集之診斷代碼及藥物代碼相關聯的第一權重及第二權重;以及對於第一代碼集之各藥物代碼,儲存具有最大值之第一權重。第一代碼集包含至少一個診斷代碼及至少一個藥物分類。資料庫包括在診斷代碼與藥物代碼之間的第一權重及在藥物代碼與另一藥物代碼之間的第二權重,且第一權重及第二權重大於零。In one aspect, according to some embodiments, a method for processing prescriptions includes: receiving a first code set; outputting diagnostic codes and drug codes of the first code set to a database; receiving and receiving the first code from the database The first weight and the second weight associated with the diagnostic code and the medicine code in the set; and for each medicine code in the first code set, the first weight with the largest value is stored. The first code set includes at least one diagnostic code and at least one drug classification. The database includes a first weight between a diagnostic code and a medicine code and a second weight between the medicine code and another medicine code, and the first weight and the second weight are greater than zero.
在一個態樣中,根據一些實施例,用於判定診斷代碼與藥物代碼之間的相關性之方法包含:接收來自與至少一個處理器通訊之資料庫之診斷代碼與藥物代碼之間的第一權重;以及對於各藥物代碼,將具有最大值之第一權重輸出至與至少一個處理器通訊之資料庫。In one aspect, according to some embodiments, the method for determining the correlation between the diagnostic code and the drug code includes: receiving the first data between the diagnostic code and the drug code from a database in communication with at least one processor. Weight; and for each drug code, output the first weight with the maximum value to the database communicating with at least one processor.
亦考量本發明之其他態樣及實施例。前述發明內容及以下實施方式並非意謂將本發明限於任何特定實施例,而僅意謂描述本發明之一些實施例。Other aspects and embodiments of the present invention are also considered. The foregoing summary of the invention and the following embodiments are not meant to limit the present invention to any specific embodiments, but only to describe some embodiments of the present invention.
本發明包含用於辨識病症-藥物以及藥物-藥物之間的相關性且計算其相關強度之自動化技術。所有自藥物大資料(亦即,處方)衍生之診斷-藥物(DM)及藥物-藥物(MM)相關性及其相關權重儲存於知識資料庫中。以下實例說明該知識資料庫,其醫療大資料借自臺灣國民健康保險研究資料庫(Taiwan National Health Insurance Research Database)。The present invention includes automated technology for identifying the correlation between disease-drug and drug-drug and calculating the strength of the correlation. All diagnostic-drug (DM) and drug-drug (MM) correlations derived from big data of drugs (that is, prescriptions) and their related weights are stored in the knowledge database. The following example illustrates the knowledge database. The medical information is borrowed from the Taiwan National Health Insurance Research Database (Taiwan National Health Insurance Research Database).
自2002年收集總共2.636億處方之臺灣國民健康保險(NHI)理賠資料。所有資料係關於臺灣醫院及診所之門診訪視。各記錄(亦即處方)由NHI代碼中之訪視日期、患者之偽ID、年齡、性別、初次診斷及二次診斷組成。各處方亦包括一至三個診斷代碼及1至15個藥物代碼。由於以下原因排除1.601億處方:(a)遺失或無效病症代碼或藥物代碼;以及(b)中藥處方之使用。因此,具有2.045億個診斷ICD-9-CM (疾病及相關健康問題之國際統計分類系統(International Statistical Classification of Diseases and Related Health Problems),第9修訂版,臨床修改)代碼之剩餘1.035億處方及3.477億具有臺灣NHI代碼之藥物用於分析。此等藥物代碼映射至ATC (解剖學治療化學(Anatomical Therapeutic Chemical))分類代碼系統。資料集由13,070個獨特ICD-9-CM代碼及1,548個獨特ATC代碼組成。在一些實施例中,使用ICD-10 (疾病及相關健康問題之國際統計分類系統,第10修訂版)、ICD-10-CM (疾病及相關健康問題之國際統計分類系統,第10修訂版,臨床修改)或ICD-10-TM (疾病及相關健康問題之國際統計分類系統,第10修訂版,泰國修改)之診斷代碼。Since 2002, it has collected a total of 263.6 million prescriptions for Taiwan National Health Insurance (NHI) claim data. All information is about outpatient visits of hospitals and clinics in Taiwan. Each record (that is, prescription) consists of the date of visit in the NHI code, the patient's pseudo ID, age, gender, first diagnosis and second diagnosis. Each prescription also includes one to three diagnostic codes and 1 to 15 drug codes. 160.1 million prescriptions were excluded due to the following reasons: (a) missing or invalid disease codes or drug codes; and (b) the use of Chinese medicine prescriptions. Therefore, the remaining 103.5 million prescriptions with 204.5 million diagnostic ICD-9-CM (International Statistical Classification of Diseases and Related Health Problems (International Statistical Classification of Diseases and Related Health Problems), 9th revised edition, clinical modification) codes and 347.7 million drugs with Taiwan’s NHI code were used for analysis. These drug codes are mapped to the ATC (Anatomical Therapeutic Chemical) classification code system. The data set consists of 13,070 unique ICD-9-CM codes and 1,548 unique ATC codes. In some embodiments, ICD-10 (International Statistical Classification System of Diseases and Related Health Problems, 10th revised edition), ICD-10-CM (International Statistical Classification System of Diseases and Related Health Problems, 10th revised edition) are used in some embodiments. Clinical revision) or ICD-10-TM (International Statistical Classification System of Diseases and Related Health Problems, 10th revised edition, revised by Thailand).
根據本發明之一實施例,病症-藥物及藥物-藥物之組合由於其共同出現於醫師對各患者之就診處方中而相關聯。相對於其在獨立假設下之預期機率,病症-藥物及藥物-藥物之權重(或相關強度值)限定診斷-藥物及藥物-藥物之聯合機率之間的比率。權重標示為Q。病症-藥物及藥物-藥物之權重分別由QDM 及QMM 表示。According to an embodiment of the present invention, the combination of the disease-drug and the drug-drug is related because they appear together in the doctor's prescription for each patient. Relative to its expected probability under the independent hypothesis, the weight (or related intensity value) of the disease-drug and the drug-drug defines the ratio between the diagnosis-drug and the drug-drug combination probability. The weight is labeled Q. The weights of disease-drug and drug-drug are represented by Q DM and Q MM respectively.
基於此定義,使用2×2圖表(參見表1)計算各DM及MM對相關強度。在此圖表中,對於給定規則(X->Y),「a」表示含有X及Y兩者之資料庫中之交易數目,「b」為含有X但不含Y之數目,「c」為含有Y但不含X之數目,及「d」為皆不含有X或Y之數目。C1及C2分別為對病症及藥物所開具之處方之總數目。
根據公式1,QXY 介於[0, +∞]之範圍內;其中QXY =1表明診斷與藥物之間無相關性,QXY <1表明診斷及藥物為負相關(亦即,負QDM ),且QXY >1表明診斷及藥物為正相關(亦即,正QDM -含有藥物Y之病症X之處方相比於其他藥物更經常出現)。在一些實施例中,QXY 經映射至[0.2, 2]之範圍。According to formula 1, Q XY is within the range of [0, +∞]; where Q XY =1 indicates that there is no correlation between the diagnosis and the drug, and Q XY <1 indicates that the diagnosis and the drug are negatively correlated (ie, negative Q DM ), and Q XY >1 indicates that the diagnosis and the drug are positively correlated (that is, positive Q DM -the disease X containing drug Y appears more often than other drugs). In some embodiments, Q XY is mapped to the range of [0.2, 2].
在處理所有觀測到的DM及MM相關性之後,吾等建立具有總共有其Q值之134萬個DM及65萬個MM對(亦即QDM 及QMM )的資料庫(術語為NHI理賠資料庫)。具有小於5次共同出現之DM及MM相關性在默認情況下視為「不常見或罕見相關性」且不包括於資料庫開發中。此外,根據本發明之一些實施例,Q之閾值為1。對於任何具有小於1之Q值的相關性(DM或MM),視為負相關或不常見相關。可調節閾值以改良系統。After processing all the observed correlations between DM and MM, we established a database of 1.34 million DM and 650,000 MM pairs (i.e. Q DM and Q MM ) with a total Q value (the term is NHI claims database). DM and MM correlations that have less than 5 co-occurrences are regarded as "uncommon or rare correlations" by default and are not included in the database development. In addition, according to some embodiments of the present invention, the threshold of Q is 1. For any correlation (DM or MM) with a Q value less than 1, it is regarded as a negative correlation or an uncommon correlation. The threshold can be adjusted to improve the system.
本發明提供一種用於處理處方之系統。參看圖1,系統基本上包含電腦1、資料庫2及用戶端3。電腦1、資料庫2及用戶端3處於通訊中。在一個實施例中,電腦1及資料庫2處於通訊中,且電腦1及用戶端3處於通訊中。The present invention provides a system for processing prescriptions. Referring to Figure 1, the system basically includes a computer 1, a database 2, and a client 3. The computer 1, the database 2 and the client 3 are in communication. In one embodiment, the computer 1 and the database 2 are in communication, and the computer 1 and the client 3 are in communication.
在一些實施例中,用戶端3包括至少一個非暫時性電腦可讀媒體,其具有儲存於其中之電腦可執行指令;至少一個處理器,其耦接至至少一個非暫時性電腦可讀媒體;及輸入/輸出模組。至少一個非暫時性電腦可讀媒體及電腦可執行指令與至少一個處理器經組態以使得裝置執行不同操作。在一個實施例中,醫師使用用戶端3輸入處方。用戶端3可為個人電腦、智慧器件或攜帶型電子器件。由醫師輸入之處方轉化為或記錄為代碼集。代碼集包含至少一個診斷代碼及至少一個藥物代碼。診斷代碼可映射至以下中之一者:ICD-9-CM、ICD-10、ICD-10-CM及ICD-10-TM代碼系統。藥物代碼可映射至ATC代碼系統、LOINC (邏輯觀察標識符名稱及代碼(Logical Observation Identifiers Names and Codes))代碼系統或SNOMED (醫學系統化命名法(Systematized Nomenclature of Medicine))代碼系統。代碼集輸出至電腦1。In some embodiments, the client 3 includes at least one non-transitory computer-readable medium having computer-executable instructions stored therein; at least one processor coupled to at least one non-transitory computer-readable medium; And input/output modules. At least one non-transitory computer-readable medium and computer-executable instructions and at least one processor are configured to cause the device to perform different operations. In one embodiment, the physician uses the user terminal 3 to input the prescription. The user terminal 3 can be a personal computer, a smart device or a portable electronic device. The prescription entered by the physician is converted or recorded as a code set. The code set includes at least one diagnostic code and at least one medication code. The diagnostic code can be mapped to one of the following: ICD-9-CM, ICD-10, ICD-10-CM and ICD-10-TM code system. The drug code can be mapped to the ATC code system, the LOINC (Logical Observation Identifiers Names and Codes) code system, or the SNOMED (Systematized Nomenclature of Medicine) code system. The code set is output to the computer 1.
電腦1接收代碼集。電腦1可為伺服器。在一些實施例中,電腦1包含中央處理單元(CPU) 11 (或處理器)、記憶體12 (或非暫時性電腦可讀媒體)及輸入/輸出模組13。CPU 11、記憶體12及輸入/輸出模組13處於通訊中。在一些實施例中,記憶體12具有儲存於其中之電腦可執行指令。記憶體12及電腦可執行指令與CPU 11經組態以使得電腦1執行不同操作。電腦1將代碼集之診斷代碼及藥物代碼輸出至資料庫2。Computer 1 receives the code set. Computer 1 can be a server. In some embodiments, the computer 1 includes a central processing unit (CPU) 11 (or processor), a memory 12 (or a non-transitory computer-readable medium), and an input/output module 13. The
在一些實施例中,資料庫2包括至少一個非暫時性電腦可讀媒體,其具有儲存於其中之電腦可執行指令;至少一個處理器,其耦接至至少一個非暫時性電腦可讀媒體;及輸入/輸出模組。至少一個非暫時性電腦可讀媒體及電腦可執行指令與至少一個處理器經組態以使得裝置執行不同操作。資料庫2接收代碼集。資料庫2包括診斷代碼與藥物代碼之間的QDM 值及藥物代碼與另一藥物代碼之間的QMM 值。在一些實施例中,QDM 值及QMM 值大於零。在一些實施例中,QDM 值及QMM 值介於[0, +∞]之範圍內。在一些實施例中,QDM 值及QMM 值在0.2與2之間(亦即,在[0, 2]之範圍內)。資料庫2將與所接收之代碼集的診斷代碼及藥物代碼相關聯之QDM 值及QMM 值輸出至電腦1。In some embodiments, the database 2 includes at least one non-transitory computer-readable medium having computer-executable instructions stored therein; at least one processor coupled to at least one non-transitory computer-readable medium; And input/output modules. At least one non-transitory computer-readable medium and computer-executable instructions and at least one processor are configured to cause the device to perform different operations. Database 2 receives the code set. The database 2 includes the Q DM value between the diagnostic code and the drug code and the Q MM value between the drug code and another drug code. In some embodiments, the Q DM value and the Q MM value are greater than zero. In some embodiments, the Q DM value and the Q MM value are in the range of [0, +∞]. In some embodiments, the Q DM value and the Q MM value are between 0.2 and 2 (that is, in the range of [0, 2]). The database 2 outputs the Q DM value and Q MM value associated with the diagnostic code and drug code of the received code set to the computer 1.
電腦1自資料庫2接收QDM 值及QMM 值。基於代碼集之QDM 值及QMM 值,電腦1處理處方。特定而言,電腦1判定處方是否滿足以下準則: (1)大於閾值之QDM 值及大於閾值之QMM 值之總數目大於或等於代碼集之藥物代碼數目; (2)代碼集之各診斷代碼具有至少一個大於閾值之QDM 值;以及 (3)代碼集之各藥物代碼具有至少一個大於閾值之QDM 值或具有至少一個大於閾值之QMM 值。The computer 1 receives the Q DM value and the Q MM value from the database 2. Based on the Q DM value and Q MM value of the code set, the computer 1 processes the prescription. Specifically, the computer 1 determines whether the prescription meets the following criteria: (1) The total number of Q DM values greater than the threshold and Q MM values greater than the threshold is greater than or equal to the number of drug codes in the code set; (2) Each diagnosis of the code set The code has at least one Q DM value greater than the threshold; and (3) each drug code of the code set has at least one Q DM value greater than the threshold or has at least one Q MM value greater than the threshold.
以上三個準則在數學上表達為:公式2The above three criteria are expressed mathematically as: Formula 2
在公式2中,n為診斷代碼之數目;m為藥物之數目;α為閾值。QDiMj 指示在第i個診斷代碼與第j個藥物代碼之間的QDM 值;QMjMk 指示在第j個藥物代碼與第k個藥物代碼之間的QMM 值。在本發明中,閾值α默認設定為1。In formula 2, n is the number of diagnostic codes; m is the number of drugs; α is the threshold. Q DiMj indicates the Q DM value between the i-th diagnostic code and the j-th drug code; Q MjMk indicates the Q MM value between the j-th drug code and the k-th drug code. In the present invention, the threshold α is set to 1 by default.
圖2為處方之一實例之示意圖,其中D1、D2及D3為處方中之診斷代碼,且M1、M2、M3、M4、M5為藥物代碼。在一個實施例中,電腦1將診斷代碼D1、D2、D3及藥物代碼M1、M2、M3、M4、M5輸出至資料庫。資料庫2接收診斷代碼D1至D3及藥物代碼M1至M5,且將相關QDM 值及QMM 值輸出至電腦1。在圖2之實施例中,資料庫輸出QD1M1 、QD1M2 、QD2M3 、QD3M4 、QM1M2 、QM1M3 、QM1M4 、QM1M5 、QM2M3 、QM2M4 、QM2M5 、QM3M4 、QM3M5 及QM4M5 。在圖2之實施例中,QD1M1 、QD1M2 、QD2M3 、QD3M4 及QM1M5 為正相關,且QM1M2 、QM1M3 、QM1M4 、QM2M3 、QM2M4 、QM2M5 、QM3M4 、QM3M5 及QM4M5 為負相關。QD1M1 、QD1M2 、QD2M3 、QD3M4 及QM1M5 大於閾值(默認設定為1),且QM1M2 、QM1M3 、QM1M4 、QM2M3 、QM2M4 、QM2M5 、QM3M4 、QM3M5 及QM4M5 小於閾值(默認設定為1)。Figure 2 is a schematic diagram of an example of a prescription, where D1, D2, and D3 are the diagnostic codes in the prescription, and M1, M2, M3, M4, and M5 are the drug codes. In one embodiment, the computer 1 outputs the diagnostic codes D1, D2, D3 and the medicine codes M1, M2, M3, M4, and M5 to the database. The database 2 receives the diagnostic codes D1 to D3 and the drug codes M1 to M5, and outputs the relevant Q DM values and Q MM values to the computer 1. In the embodiment of FIG. 2 of, the library Output Q D1M1, Q D1M2, Q D2M3 , Q D3M4, Q M1M2, Q M1M3, Q M1M4, Q M1M5, Q M2M3, Q M2M4, Q M2M5, Q M3M4, Q M3M5 and Q M4M5 . In the embodiment of FIG. 2 of the, Q D1M1, Q D1M2, Q D2M3, Q D3M4 and Q M1M5 positive correlation, and Q M1M2, Q M1M3, Q M1M4 , Q M2M3, Q M2M4, Q M2M5, Q M3M4, Q M3M5 And Q M4M5 is negatively correlated. Q D1M1, Q D1M2, Q D2M3 , Q D3M4 and Q M1M5 greater than a threshold value (defaults to 1), and Q M1M2, Q M1M3, Q M1M4 , Q M2M3, Q M2M4, Q M2M5, Q M3M4, Q M3M5 and Q M4M5 Less than the threshold (default setting is 1).
在一些實施例中,若電腦1判定代碼集滿足所有三個準則,則電腦1將不傳送訊息或警示至用戶端3,例如以檢查對應處方是否為適當的。在一些實施例中,若電腦1判定代碼集不滿足所有三個準則,則電腦1將傳送訊息或警示至用戶端3,例如以檢查對應處方是否為適當的,且將訊息輸出至用戶端3。In some embodiments, if the computer 1 determines that the code set meets all three criteria, the computer 1 will not send a message or alert to the client 3, for example, to check whether the corresponding prescription is appropriate. In some embodiments, if the computer 1 determines that the code set does not meet all three criteria, the computer 1 will send a message or alert to the client 3, for example, to check whether the corresponding prescription is appropriate, and output the message to the client 3. .
在一些實施例中,若用戶端3接收來自電腦1之表明代碼集不滿足所有三個準則之訊息,則用戶端3警告或通知醫師或藥劑師檢查對應處方是否為適當的或應經修改。In some embodiments, if the client 3 receives a message from the computer 1 indicating that the code set does not meet all three criteria, the client 3 warns or informs the physician or pharmacist to check whether the corresponding prescription is appropriate or should be modified.
本發明已由人類專家評估。首先,本發明基於驗證資料集進行初始測試。隨後,由包括四名醫師及三名臨床藥劑師之人類專家對系統進行第二次評估以量測本發明之精確性。The present invention has been evaluated by human experts. First, the present invention conducts initial testing based on the verification data set. Subsequently, human experts including four physicians and three clinical pharmacists conducted a second evaluation of the system to measure the accuracy of the present invention.
圖3為根據本發明之一些實施例之驗證及測試本發明之流程圖。在操作31中,100,000個處方係隨機選自2003 NHI資料庫。然後,本發明用於幫助醫師及藥劑師測試所選擇處方之適當性。在總共100,000個處方中,本發明中99,004個處方(99.004%)標識為適當的,且996個處方(0.996%)標識為不當的。Figure 3 is a flow chart of verifying and testing the present invention according to some embodiments of the present invention. In
在操作32中,400個處方係隨機選自操作31中測試之100,000個處方。經選擇以由專家(例如醫師或藥劑師)評估之400個處方包括254個(63.5%)適當處方及146個(36.5%)不當處方。為了有助於標識及量測處方,所有專家解釋研究之用途且要求標示關於提供給該等專家之總體處方資料,該等專家是否同意、反對或不確定。接著,用兩種類型之調查表再評估相同處方-需要或無需展示存在於處方中之各DM相關性之Q值。適當及不當處方經識別且混合在同一調查表內。吾等將調查表投與至在其診所之四名醫師(各醫師兩百個處方)及在醫院藥房之三名臨床藥劑師(各藥劑師八百個處方)。無Q值之調查表首先由所有專家填寫,隨後填寫有Q值之調查表。總體而言,吾等投與3,200個處方(1,600個處方無Q值及1,600個處方有Q值)。In
為了比較系統與專家之間的差異及共識,自所獲得之結果計算靈敏度、特異性、陽性預測值(PPV)及陰性預測值(NPV)。In order to compare the differences and consensus between the system and the experts, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) are calculated from the obtained results.
當不揭示Q值時,專家對1,590 (99.3%)個處方作出回應,其中1,374 (85.9%)個為適當的且216 (13.5%)個為不當處方,剩餘10個處方為「未知的」。然而,當Q值展示於處方中時,專家僅對1,587 (99.2%)個處方作出反應,其中1,313 (82.1%)個為適當的,274 (17.1%)個為不當處方,且13個處方歸類為「未知的」(參見圖3)。When the Q value was not revealed, the experts responded to 1,590 (99.3%) prescriptions, of which 1,374 (85.9%) were appropriate and 216 (13.5%) were improper prescriptions, and the remaining 10 prescriptions were “unknown”. However, when the Q value was displayed in the prescriptions, experts only responded to 1,587 (99.2%) prescriptions, of which 1,313 (82.1%) were appropriate, 274 (17.1%) were improper prescriptions, and 13 prescriptions belonged to The class is "unknown" (see Figure 3).
由臨床藥劑師評定系統之精確性且所獲得之結果展示於表2中。當揭示Q時,平均靈敏度、PPV及NPV分別為藥劑師之68.8%、95.6%及24.6%。其中展示Q值之調查表中所發現之變化不同於未展示Q值之調查表中之變化。然而,平均靈敏度、PPV及NPV分別為74.3%、98.7%及40.6%。
基於上文所描述之結果,本發明提供一種處方分析方法,其在自動標識處方中之病症-藥物及藥物-藥物之間的不常見或罕見相關性時使用機率模型作為有效工具。本發明不僅有助於藉由警示醫師檢查經標識之處方來減少藥物錯誤,而且改良了患者之安全性及健康護理之總體品質。Based on the results described above, the present invention provides a prescription analysis method that uses a probability model as an effective tool when automatically identifying uncommon or rare correlations between disease-drug and drug-drug in a prescription. The present invention not only helps to reduce medication errors by alerting physicians to check the marked prescriptions, but also improves the safety of patients and the overall quality of health care.
本發明進一步提供用於處理處方之由電腦1執行之操作。圖4為根據本發明之一些實施例之由電腦1執行之操作流程圖。在一些實施例中,記憶體12具有儲存於其中之電腦可執行指令。記憶體12及電腦可執行指令與CPU 11經組態以使得電腦1執行操作。The present invention further provides operations executed by the computer 1 for processing prescriptions. FIG. 4 is a flowchart of operations executed by the computer 1 according to some embodiments of the present invention. In some embodiments, the memory 12 has computer-executable instructions stored therein. The memory 12 and computer executable instructions and the
在操作41中,電腦1接收代碼集。代碼集包含至少一個診斷代碼及至少一個藥物代碼。在一些實施例中,自用戶端3接收代碼集,醫師在該用戶端上輸入處方。診斷代碼可映射至以下中之一者:ICD-9-CM、ICD-10、ICD-10-CM及ICD-10-TM代碼系統。藥物代碼可映射至ATC代碼系統、LOINC (邏輯觀察標識符名稱及代碼)代碼系統或SNOMED (醫學系統化命名)代碼系統。In
在操作42中,電腦1將所接收之代碼集輸出至資料庫2。資料庫2包括診斷代碼與藥物代碼之間的QDM
值及藥物代碼與另一藥物代碼之間的QMM
值。在一些實施例中,資料庫2根據輸入診斷代碼及藥物代碼查詢相關QDM
值及QMM
值且將其輸出。In
在操作43中,電腦1接收與輸出至資料庫2之代碼集相關聯之QDM
值及QMM
值。In
在操作44、45及46中,電腦1判定所接收之代碼集是否滿足準則。特定而言,電腦1判定與代碼集相關聯之QDM
值及QMM
值是否滿足所有以下三個準則:
(1)大於閾值之QDM
值及大於閾值之QMM
值之總數目大於或等於代碼集之藥物代碼數目;
(2)代碼集之各診斷代碼具有至少一個大於閾值之QDM
值;以及
(3)代碼集之各藥物代碼具有至少一個大於閾值之QDM
值或具有至少一個大於閾值之QMM
值(閾值默認設定為1)。In
在一些實施例中,判定與代碼集相關聯之QDM
值及QMM
值是否滿足所有以下三個準則(亦即操作44、45及46)可利用旗標來探索。電腦1生成旗標。電腦1默認設定旗標等於0。電腦1將大於閾值之QDM
值及大於閾值之QMM
值之總數目與代碼集之藥物代碼數目進行比較。若大於閾值之第一代碼集之第一權重及大於閾值之第一代碼集之第二權重的總數目小於第一代碼集之藥物代碼數目,則電腦1設定旗標等於1;對於代碼集之各診斷代碼,電腦1將QDM
值與閾值進行比較。若代碼集之診斷代碼之QDM
值小於或等於閾值,則電腦1設定旗標等於1。對於代碼集之各藥物代碼,電腦1比較QDM
值與閾值且比較QMM
值與閾值。若代碼集之藥物代碼之QDM
值及QMM
值小於或等於閾值,則電腦1設定旗標等於1。若旗標等於0,則與代碼集相關聯之QDM
值及QMM
值滿足以上所有三個準則。若旗標等於1,則與代碼集相關聯之QDM
值及QMM
值不滿足以上所有三個準則。In some embodiments, determining whether the Q DM value and the Q MM value associated with the code set satisfy all the following three criteria (ie,
若與代碼集相關聯之QDM
值及QMM
值滿足以上所有三個準則,則電腦1將不輸出訊息。若與代碼集相關聯之QDM
值及QMM
值不滿足以上所有三個準則,則電腦1在操作47中輸出訊息。在一些實施例中,電腦1在操作47中將訊息輸出至用戶端3。在一些實施例中,若用戶端3自電腦1接收表明代碼集不滿足所有三個準則之訊息,則用戶端3警告或通知醫師檢查對應處方是否為適當的或應經修改。 If the Q DM value and Q MM value associated with the code set meet all the above three criteria, computer 1 will not output a message. If the Q DM value and Q MM value associated with the code set do not satisfy all three criteria above, the computer 1 outputs a message in
圖5為根據本發明之一些實施例之由電腦1執行之操作流程圖。在一些實施例中,記憶體12具有儲存於其中之電腦可執行指令。記憶體12及電腦可執行指令與CPU 11經組態以使得電腦1執行操作。FIG. 5 is a flowchart of operations executed by the computer 1 according to some embodiments of the present invention. In some embodiments, the memory 12 has computer-executable instructions stored therein. The memory 12 and computer executable instructions and the
在操作51中,電腦1接收代碼集。代碼集包含至少一個診斷代碼及至少一個藥物代碼。在一些實施例中,自用戶端3接收代碼集,醫師在該用戶端上輸入處方。診斷代碼可映射至以下中之一者:ICD-9-CM、ICD-10、ICD-10-CM及ICD-10-TM代碼系統。藥物代碼可映射至ATC代碼系統、LOINC (邏輯觀察標識符名稱及代碼)代碼系統或SNOMED (醫學系統化命名)代碼系統。In
在操作52中,電腦1將所接收之代碼集輸出至資料庫2。資料庫2包括診斷代碼與藥物代碼之間的QDM
值及藥物代碼與另一藥物代碼之間的QMM
值。在一些實施例中,資料庫2根據輸入診斷代碼及藥物代碼查詢相關QDM
值及QMM
值且將其輸出。In
在操作53中,電腦1接收與輸出至資料庫2之代碼集相關聯之QDM
值及QMM
值。In
在自處方資料庫生成QDM 值及QMM 值或在該處方資料庫(例如NHI理賠資料庫)中採擷該等值期間,可出現一些錯誤的診斷-藥物相關性(偽相關性)。舉例而言,抗高血壓藥劑可相對於高血壓及糖尿病兩者具有高相關性,此係因為糖尿病患者經常患有高血壓。因此,抗高血壓藥劑經常存在於具有高血壓及糖尿病之診斷的處方中。由於此原因,抗高血壓藥劑相對於高血壓具有高QDM 值且相對於糖尿病具有高QDM 值。然而,抗高血壓藥劑與糖尿病不應具有高QDM 值。抗高血壓藥劑與糖尿病之間的高相關性稱為偽相關性。During the generation of the Q DM value and Q MM value from the prescription database or the acquisition of these values in the prescription database (such as the NHI claims database), some false diagnosis-drug correlations (pseudo correlations) may occur. For example, antihypertensive agents may have a high correlation with both hypertension and diabetes, because diabetic patients often suffer from hypertension. Therefore, antihypertensive agents are often present in prescriptions with the diagnosis of hypertension and diabetes. For this reason, anti-hypertensive agent with respect to the blood pressure value and a high Q DM diabetes have a high relative value Q DM. However, antihypertensive agents and diabetes should not have high Q DM values. The high correlation between antihypertensive agents and diabetes is called pseudo-correlation.
在操作54中,對於代碼集之各藥物代碼,電腦1僅儲存最大QDM
值且丟棄其他QDM
值(或僅儲存與最大QDM
值之相關性)。對於具有抗高血壓藥劑、高血壓及糖尿病之處方之實例,因為並非每一個糖尿病患者遭受高血壓,儘管抗高血壓藥劑相對於高血壓具有高QDM
值且相對於糖尿病具有高QDM
值,但抗高血壓藥劑與高血壓之間的QDM
值大於抗高血壓藥劑與糖尿病之間的QDM
值。在操作54之後,去除抗高血壓藥劑與糖尿病之間的偽相關性。In
根據一些實施例,在操作54中,對於代碼集之各藥物代碼,電腦1不僅儲存最大QDM
值,而且儲存與最大QDM
值之同一組診斷代碼中之診斷代碼相關聯之QDM
值。對於具有抗高血壓藥劑、原發性高血壓、良性原發性高血壓及糖尿病之處方之實例,因為抗高血壓藥劑與原發性高血壓之間之QDM
值(例如在ICD-9-CM代碼系統中之診斷代碼401)為最大值,儲存抗高血壓藥劑與原發性高血壓之間的最大QDM
值,且亦儲存與處於與原發性高血壓同一組中之良性原發性高血壓相關聯的QDM
值(例如診斷代碼4011,良性原發性高血壓)。According to some embodiments, in
根據一些實施例,在操作54中,對於各藥物代碼,電腦1不僅儲存具有最大QDM
值之相關性,而且儲存具有與最大QDM
值之同一組診斷代碼中之診斷代碼相關聯之QDM
值的相關性。對於具有抗高血壓藥劑、原發性高血壓、良性原發性高血壓及糖尿病之處方之實例,因為抗高血壓藥劑與原發性高血壓之間的QDM
值(例如在ICD-9-CM代碼系統中之診斷代碼401)為最大值,儲存抗高血壓藥劑與原發性高血壓之間的最大QDM
值,且亦儲存具有處於與原發性高血壓同一組中之良性原發性高血壓相關聯之QDM
值的相關性(例如診斷代碼4011,良性原發性高血壓)。According to some embodiments, in
在操作55中,電腦1判定所接收之代碼集是否滿足如操作44、45及46中所揭示之所有三個準則。特定而言,操作55包含圖4中所展示之操作44、45及46。在操作55中,若電腦1判定與代碼集相關聯之所儲存之QDM
值及QMM
值滿足如圖4中所展示的操作44、45及46中所揭示之所有三個準則,則電腦1將不輸出訊息。In
在操作55中,若電腦1判定與代碼集相關聯之所儲存之QDM
值及QMM
值不滿足如圖4中所展示的操作44、45及46中所揭示之所有三個準則,則電腦1在操作56中輸出訊息。在一些實施例中,電腦1在操作56中將訊息輸出至用戶端3。在一些實施例中,若用戶端3自電腦1接收表明代碼集不滿足所有三個準則之訊息,則用戶端3警告或通知醫師檢查對應處方是否為適當的或應經修改。In
表3展示根據表1及公式1計算QDM
值之五個例示性處方。表4展示原發性高血壓(亦即診斷代碼(ICD9) 4019)與用於糖尿病之藥物(亦即藥物代碼(ATC代碼) A10AB03、A10AB04、A10AC01、A10AD05、A10AE05、A10BA02、A10BA03、A10BB01、A10BB02及A10BB07)之間的QDM
值。表4展示原發性高血壓與用於糖尿病之藥物之間的相關性為高度陽性的。展示於表4中之原發性高血壓與用於糖尿病之藥物之間的相關性稱為偽相關性。若不去除展示於表4中之偽相關性,則處方之處理將為錯誤的。
圖6為根據本發明之一些實施例之由電腦1執行之操作流程圖。在一些實施例中,記憶體12具有儲存於其中之電腦可執行指令。記憶體12及電腦可執行指令與CPU 11經組態以使得電腦1執行操作。FIG. 6 is a flowchart of operations executed by the computer 1 according to some embodiments of the present invention. In some embodiments, the memory 12 has computer-executable instructions stored therein. The memory 12 and computer executable instructions and the
在操作61中,電腦1接收代碼集。代碼集包含至少一個診斷代碼及至少一個藥物代碼。在一些實施例中,自用戶端3接收代碼集,醫師在該用戶端上輸入處方。診斷代碼可映射至以下中之一者:ICD-9-CM、ICD-10、ICD-10-CM及ICD-10-TM代碼系統。藥物代碼可映射至ATC代碼系統、LOINC (邏輯觀察標識符名稱及代碼)代碼系統或SNOMED (醫學系統化命名)代碼系統。In
在操作62中,電腦1判定所接收之代碼集是否滿足如操作44、45及46中所揭示之所有三個準則。特定而言,操作62包含圖4中所展示之操作42、43、44、45及46。在操作62中,電腦1將所接收之代碼集輸出至資料庫2,接收與輸出至資料庫2之代碼集相關聯之QDM
值及QMM
值,且判定與代碼集相關聯之所儲存之QDM
值及QMM
值是否滿足圖4中所展示之操作44、45及46的所有三個準則。在操作62中,若電腦1判定與代碼集相關聯之所儲存之QDM
值及QMM
值滿足如圖4中所展示的操作44、45及46中所揭示之所有三個準則,則電腦1將不輸出訊息。In
在操作62中,若電腦1判定所接收之代碼集不滿足如圖4中所展示的操作44、45及46中所揭示之所有三個準則,則電腦1在操作63中輸出訊息。在一些實施例中,電腦1在操作63中將訊息輸出至用戶端3。在一些實施例中,電腦1將至少一個藥物代碼輸出至用戶端3。自電腦1輸出至用戶端3之至少一個藥物代碼具有至少一個小於閾值(默認設定為1)之QDM
值或具有至少一個小於閾值(默認設定為1)之QMM
值。亦即,由電腦1輸出之至少一個藥物代碼與所接收之代碼集之一個診斷代碼具有至少一個負相關或與所接收之代碼集的另一藥物代碼具有至少一個負相關。在一些實施例中,若用戶端3自電腦1接收表明所接收之代碼集不滿足如圖4中所展示的操作44、45及46中所揭示之所有三個準則之訊息,則用戶端3通知或警告醫師檢查對應處方是否為適當的或應經修改。在一些實施例中,若用戶端3自電腦1接收表明所接收之代碼集不滿足如圖4中所展示的操作44、45及46中所揭示之所有三個準則的至少一個藥物代碼,則用戶端3通知(或警告)醫師至少一個可經修改的藥物代碼且通知(或警告)醫師檢查對應藥物是否為適當的或應經修改。In
在操作64中,電腦1判定代碼集(其不滿足所有三個準則)是否經修改。特定而言,若代碼集(其不滿足所有三個準則)在一時間段內未經修改(例如,啟用用戶端3),則電腦1接收第一類型之訊息。除此以外,若代碼集(其不滿足所有三個準則)在一時間段內經修改(例如啟用用戶端3),則電腦1接收第二類型之訊息。In
若電腦1在操作64中接收第二類型之訊息,則電腦1執行操作65以接收另一代碼集(例如自用戶端3)。在操作65之後,電腦1執行操作62以判定操作65中所接收之代碼集是否滿足如操作44、45及46中所揭示之所有三個準則。If the computer 1 receives the second type of message in
若電腦1在操作64中接收第一類型之訊息,則電腦1執行操作66以更新在操作63中輸出之與所輸出藥物代碼相關聯的QDM
值及QMM
值。特定而言,電腦1更新在操作63中輸出之與所輸出藥物代碼相關聯的資料庫2中(或儲存於其中)的QDM
值及QMM
值。在一些實施例中,電腦1更新在操作63中輸出之與所輸出藥物代碼相關聯之小於閾值(默認設定為1)的QDM
值及QMM
值。If the computer 1 receives the first type of message in
在一些實施例中,藉由QDM 值及QMM 值乘以一個數來更新QDM 值及QMM 值。在一些實施例中,待相乘之數大於1。在一些實施例中,藉由QDM 值及QMM 值與一個數相加來更新QDM 值及QMM 值。在一些實施例中,待相加之數大於0。In some embodiments, by the value of Q DM and Q MM to update the value of a number is multiplied by the value of Q DM and Q MM value. In some embodiments, the number to be multiplied is greater than one. In some embodiments, the DM Q value by MM and a number Q value updated by adding the value of the DM and Q values Q MM. In some embodiments, the number to be added is greater than zero.
因為一些藥物係基於新適應症、標籤外使用或醫師之經驗,所以此等藥物可判定為不滿足如圖4中所展示的操作44、45及46中所揭示之所有三個準則,且將出現頻繁警告或通知。負責處方之醫師已檢查由本發明產生之警示或通知,且醫師決定不修改處方。更新在操作63中輸出之與藥物代碼相關聯之QDM
值及QMM
值以避免頻繁警示或通知。Because some drugs are based on new indications, off-label use, or physician experience, these drugs can be determined as not meeting all three criteria disclosed in
在操作67中,電腦1將所接收之代碼確證為滿足如圖4中所展示之操作44、45及46中所揭示之所有三個準則。因為醫師已檢查表明代碼集(亦即處方)不滿足所有三個準則之警示或通知且決定不修改處方,所以代碼集(亦即處方)已由醫師進行雙重檢查。因此,應相信在操作67中確證所接收之代碼集滿足所有三個準則。In
藉由938個通知(例如在操作63中發送之訊息)及12名專家(例如醫師或藥劑師)對圖6中所展示之操作執行驗證。在結果中,對於每三名專家,存在一名專家以85%之百分比同意通知。應請注意,在無更新QDM
及QMM
值(例如操作66及67)之操作的情況下,專家以低於30%之百分比同意通知。The operation shown in FIG. 6 is verified by 938 notifications (for example, the message sent in operation 63) and 12 experts (for example, physicians or pharmacists). In the result, for every three experts, there is one expert who agrees to the notification at a percentage of 85%. It should be noted that in the absence of operations to update the Q DM and Q MM values (such as
圖7為根據本發明之一些實施例之由電腦1執行之操作流程圖。在一些實施例中,記憶體12具有儲存於其中之電腦可執行指令。記憶體12及電腦可執行指令與CPU 11經組態以使得電腦1執行操作。FIG. 7 is a flowchart of operations executed by the computer 1 according to some embodiments of the present invention. In some embodiments, the memory 12 has computer-executable instructions stored therein. The memory 12 and computer executable instructions and the
圖7中所展示之操作為圖5及圖6中所展示操作之組合。特定而言,圖5中之操作51、52、53、54及55及操作63、64、65、66及67應用於圖7。為簡單起見,圖7之細節不在此處描述,請參考上文操作51、52、53、54、55、63、64、65、66及67之揭示內容。基於上文操作51、52、53、54、55、63、64、65、66及67之揭示內容,熟習此項技術者應理解圖7中所展示之操作。The operation shown in FIG. 7 is a combination of the operations shown in FIG. 5 and FIG. 6. Specifically,
圖8為根據本發明之一些實施例之由電腦1執行之操作流程圖。在一些實施例中,記憶體12具有儲存於其中之電腦可執行指令。記憶體12及電腦可執行指令與CPU 11經組態以使得電腦1執行操作。FIG. 8 is a flowchart of operations executed by the computer 1 according to some embodiments of the present invention. In some embodiments, the memory 12 has computer-executable instructions stored therein. The memory 12 and computer executable instructions and the
在一些實施例中,在計算如段落0020至0023中所揭示之病症-藥物之權重(QDM 值)及藥物-藥物之權重(QMM 值)之後,執行圖8中所展示之操作。在一些實施例中,圖8中所展示之操作可用於進一步處理儲存於資料庫2中之QDM 值及QMM 值。In some embodiments, after calculating the disease-drug weight (Q DM value) and the drug-drug weight (Q MM value) as disclosed in paragraphs 0020 to 0023, the operations shown in FIG. 8 are performed. In some embodiments, the operations shown in FIG. 8 can be used to further process the Q DM values and Q MM values stored in the database 2.
在自處方資料庫生成QDM 值及QMM 值或在該處方資料庫(例如NHI理賠資料庫)中採擷該等值期間,可出現一些錯誤的診斷-藥物相關性(偽相關性)。舉例而言,抗高血壓藥劑可相對於高血壓及糖尿病兩者具有高相關性,此係因為糖尿病患者經常患有高血壓。因此,抗高血壓藥劑經常存在於具有高血壓及糖尿病之診斷的處方中。由於此原因,抗高血壓藥劑相對於高血壓具有高QDM 值且相對於糖尿病具有高QDM 值。然而,抗高血壓藥劑與糖尿病不應具有高QDM 值。抗高血壓藥劑與糖尿病之間的高相關性稱為偽相關性。During the generation of the Q DM value and Q MM value from the prescription database or the acquisition of these values in the prescription database (such as the NHI claims database), some false diagnosis-drug correlations (pseudo correlations) may occur. For example, antihypertensive agents may have a high correlation with both hypertension and diabetes, because diabetic patients often suffer from hypertension. Therefore, antihypertensive agents are often present in prescriptions with the diagnosis of hypertension and diabetes. For this reason, anti-hypertensive agent with respect to the blood pressure value and a high Q DM diabetes have a high relative value Q DM. However, antihypertensive agents and diabetes should not have high Q DM values. The high correlation between antihypertensive agents and diabetes is called pseudo-correlation.
在操作81中,電腦1接收QDM
值。在一些實施例中,診斷代碼可映射至ICD-9-CM、ICD-10、ICD-10-CM及ICD-10-TM代碼系統中之一者,且藥物代碼可映射至ATC代碼系統、LOINC (邏輯觀察標識符名稱及代碼)代碼系統或SNOMED (醫學系統化命名)代碼系統。In
在操作82中,對於各藥物代碼,電腦1僅儲存最大QDM
值且丟棄其他QDM
值(或僅儲存與最大QDM
值之相關性)。對於具有抗高血壓藥劑、高血壓及糖尿病之處方之實例,因為並非每一個糖尿病患者遭受高血壓,儘管抗高血壓藥劑相對於高血壓具有高QDM
值且相對於糖尿病具有高QDM
值,但抗高血壓藥劑與高血壓之間的QDM
值大於抗高血壓藥劑與糖尿病之間的QDM
值。在操作82之後,去除抗高血壓藥劑與糖尿病之間的偽相關性。In
根據一些實施例,在操作82中,對於各藥物代碼,電腦1不僅儲存具有最大QDM
值,而且儲存與最大QDM
值之同一組診斷代碼中之診斷代碼相關聯的QDM
值。對於具有抗高血壓藥劑、原發性高血壓、良性原發性高血壓及糖尿病之處方之實例,因為抗高血壓藥劑與原發性高血壓之間的QDM
值(例如在ICD-9-CM代碼系統中之診斷代碼401)為最大值,儲存抗高血壓藥劑與原發性高血壓之間的最大QDM
值,且亦儲存與處於與原發性高血壓同一組中之良性原發性高血壓相關聯的QDM
值(例如診斷代碼4011,良性原發性高血壓)。According to some embodiments, in
根據一些實施例,在操作82中,對於各藥物代碼,電腦1不僅儲存與最大QDM
值之相關性,而且儲存具有與最大QDM
值之同一組診斷代碼中之診斷代碼相關聯之QDM
值的相關性。對於具有抗高血壓藥劑、原發性高血壓、良性原發性高血壓及糖尿病之處方之實例,因為抗高血壓藥劑與原發性高血壓之間的QDM
值(例如在ICD-9-CM代碼系統中之診斷代碼401)為最大值,儲存抗高血壓藥劑與原發性高血壓之間的最大QDM
值,且亦儲存具有與處於與原發性高血壓同一組中之良性原發性高血壓相關聯之QDM
值的相關性(例如診斷代碼4011,良性原發性高血壓)。According to some embodiments, in
在操作83中,經處理之QDM
值輸出至資料庫2且儲存於資料庫2中。In
在操作81至83之後,去除QDM
值中之偽相關性。儲存至資料庫2之經處理之QDM
值及QMM
值可用於圖4中或圖6中所展示之操作。After
表5展示根據表1及公式1計算QDM 值之五個例示性處方。在無圖8中所展示之操作的情況下,表6展示原發性高血壓(亦即診斷代碼(ICD9) 4019)與用於糖尿病之藥物(亦即藥物代碼(ATC代碼) A10AB03、A10AB04、A10AC01、A10AD05、A10AE05、A10BA02、A10BA03、A10BB01、A10BB02及A10BB07)之間的QDM 值。圖6展示原發性高血壓與用於糖尿病之藥物之間的相關性為高度陽性的。展示於表6中之原發性高血壓與用於糖尿病之藥物之間的相關性稱為偽相關性。Table 5 shows five exemplary prescriptions for calculating Q DM values according to Table 1 and Formula 1. Without the operation shown in Figure 8, Table 6 shows essential hypertension (i.e. diagnostic code (ICD9) 4019) and drugs for diabetes (i.e. drug code (ATC code) A10AB03, A10AB04, A10AC01, A10AD05, A10AE05, A10BA02, A10BA03, A10BB01, A10BB02 and A10BB07) between the Q DM values. Figure 6 shows that the correlation between essential hypertension and drugs used for diabetes is highly positive. The correlation between essential hypertension and the drugs used for diabetes shown in Table 6 is called pseudo-correlation.
在圖8中所展示之操作之後,表7展示原發性高血壓(亦即診斷代碼(ICD9) 4019)與用於糖尿病之藥物(亦即藥物代碼(ATC代碼) A10AB01、A10AC01、A10AD01、A10AD05、A10BA02、A10BA03、A10BB01、A10BB02、A10BB05及A10BB07)之間的QDM
值。表7展示原發性高血壓與用於糖尿病之藥物之間的相關性為陰性的。去除展示於表6中之原發性高血壓與用於糖尿病之藥物之間的偽相關性。
除非上下文另外明確地規定,否則如本文中所使用,單數術語「一(a/an)」及「該(the)」可包括複數個指代物。舉例而言,除非上下文另外清楚地指示,否則對電子器件之參考可包括多個電子器件。Unless the context clearly dictates otherwise, as used herein, the singular terms "a/an" and "the" may include plural referents. For example, unless the context clearly dictates otherwise, a reference to an electronic device may include multiple electronic devices.
如本文中所使用,術語「連接(connected/connection)」、「通訊」及「處於通訊」係指操作耦接或鏈接。處於通訊中之組件可直接地或間接地經由例如另一組組件耦接或彼此間連接。As used herein, the terms "connected/connection", "communication" and "in communication" refer to operating coupling or linking. Components in communication can be directly or indirectly coupled or connected to each other via, for example, another set of components.
另外,量、比率及其他數值有時在本文中以範圍格式提出。應理解,此類範圍格式係為便利及簡潔起見而使用,且應靈活地理解為不僅包括明確指定為範圍限制之數值,而且包括涵蓋於彼範圍內之所有個別數值或子範圍,如同明確指定各數值及子範圍一般。In addition, quantities, ratios, and other numerical values are sometimes presented in range format in this article. It should be understood that such range formats are used for convenience and brevity, and should be flexibly understood to include not only the values explicitly designated as range limits, but also all individual values or sub-ranges covered within that range, as if clearly Specify the values and sub-ranges in general.
儘管本發明已參考其特定實施例進行描述及說明,但此等描述及說明並不為限制性的。熟習此項技術者應理解,在不脫離如由所附申請專利範圍定義的本發明之真實精神及範疇之情況下,可作出各種改變且可取代等效物。圖式可不必按比例繪製。由於製造過程及公差,在本發明中之技術再現與實際裝置之間可能存在區別。可存在並未特定說明的本發明之其他實施例。應將本說明書及附圖視為說明性而非限制性的。可作出修改,以使特定情形、材料、物質組成、方法或製程適應於本發明之目標、精神及範疇。所有此等修改意欲在此隨附之申請專利範圍之範疇內。雖然已參考按特定次序執行之特定操作來描述本文中所揭示之方法,但應理解,在不脫離本發明之教示的情況下,可組合、再細分或重新定序此等操作以形成等效方法。因此,除非本文中另外特定地指示,否則操作之次序及分組並非本發明之限制。Although the present invention has been described and illustrated with reference to specific embodiments thereof, these descriptions and illustrations are not restrictive. Those familiar with the art should understand that various changes can be made and equivalents can be substituted without departing from the true spirit and scope of the present invention as defined by the scope of the appended patent application. The diagram does not have to be drawn to scale. Due to the manufacturing process and tolerances, there may be differences between the technical reproduction in the present invention and the actual device. There may be other embodiments of the invention that are not specifically described. The description and drawings should be regarded as illustrative rather than restrictive. Modifications can be made to adapt specific situations, materials, material compositions, methods, or manufacturing processes to the objectives, spirit, and scope of the present invention. All such modifications are intended to be within the scope of the patent application attached herewith. Although the methods disclosed herein have been described with reference to specific operations performed in a specific order, it should be understood that these operations can be combined, subdivided, or reordered to form equivalents without departing from the teachings of the present invention. method. Therefore, unless specifically indicated otherwise herein, the order and grouping of operations is not a limitation of the present invention.
1:電腦 2:資料庫 3:用戶端 11:中央處理單元 12:記憶體 13:輸入/輸出模組 31:操作 32:操作 41:操作 42:操作 43:操作 44:操作 45:操作 46:操作 47:操作 51:操作 52:操作 53:操作 54:操作 55:操作 56:操作 61:操作 62:操作 63:操作 64:操作 65:操作 66:操作 67:操作 81:操作 82:操作 83:操作 D1:診斷代碼 D2:診斷代碼 D3:診斷代碼 M1:藥物代碼 M2:藥物代碼 M3:藥物代碼 M4:藥物代碼 M5:藥物代碼1: computer 2: Database 3: User side 11: Central Processing Unit 12: Memory 13: Input/output module 31: Operation 32: Operation 41: Operation 42: Operation 43: Operation 44: Operation 45: Operation 46: Operation 47: Operation 51: Operation 52: Operation 53: Operation 54: Operation 55: Operation 56: Operation 61: Operation 62: Operation 63: Operation 64: Operation 65: Operation 66: Operation 67: Operation 81: Operation 82: Operation 83: Operation D1: Diagnostic code D2: Diagnostic code D3: Diagnostic code M1: Drug code M2: Drug code M3: Drug code M4: Drug code M5: Drug code
為了更好地理解本發明之一些實施例的本質及目標,應參考結合附圖進行之以下詳細描述。在圖式中,除非另外指定,否則相同或功能上相同之元件給予相同附圖標號。In order to better understand the essence and objectives of some embodiments of the present invention, the following detailed descriptions should be made with reference to the accompanying drawings. In the drawings, unless otherwise specified, the same or functionally same elements are given the same reference numerals.
圖1說明根據本發明之一些實施例之系統。Figure 1 illustrates a system according to some embodiments of the invention.
圖2說明根據本發明之一些實施例的診斷與藥物之間的相關性。Figure 2 illustrates the correlation between diagnosis and medication according to some embodiments of the present invention.
圖3為根據本發明之一些實施例的驗證及測試流程圖。Figure 3 is a flow chart of verification and testing according to some embodiments of the present invention.
圖4為根據本發明之一些實施例的操作流程圖。Fig. 4 is a flowchart of operations according to some embodiments of the present invention.
圖5為根據本發明之一些實施例的操作流程圖。Figure 5 is a flowchart of operations according to some embodiments of the present invention.
圖6為根據本發明之一些實施例的操作流程圖。Fig. 6 is a flowchart of operations according to some embodiments of the present invention.
圖7為根據本發明之一些實施例的操作流程圖。Fig. 7 is a flowchart of operations according to some embodiments of the present invention.
圖8為根據本發明之一些實施例的操作流程圖。Fig. 8 is a flowchart of operations according to some embodiments of the present invention.
61:操作61: Operation
62:操作62: Operation
63:操作63: Operation
64:操作64: Operation
65:操作65: Operation
66:操作66: Operation
67:操作67: Operation
Claims (20)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW108132337A TWI783172B (en) | 2019-09-06 | 2019-09-06 | Apparatus and method for processing of a prescription |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW108132337A TWI783172B (en) | 2019-09-06 | 2019-09-06 | Apparatus and method for processing of a prescription |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202111723A true TW202111723A (en) | 2021-03-16 |
| TWI783172B TWI783172B (en) | 2022-11-11 |
Family
ID=76035643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108132337A TWI783172B (en) | 2019-09-06 | 2019-09-06 | Apparatus and method for processing of a prescription |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI783172B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794863B (en) * | 2021-06-02 | 2023-03-01 | 美商醫守科技股份有限公司 | Clinical association evaluating apparatus and clinical association evaluating method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150356272A1 (en) * | 2014-06-10 | 2015-12-10 | Taipei Medical University | Prescription analysis system and method for applying probabilistic model based on medical big data |
| CN106446525B (en) * | 2016-08-31 | 2019-05-10 | 杭州逸曜信息技术有限公司 | The processing method of medication Rule Information similarity |
| US20180075558A1 (en) * | 2016-09-12 | 2018-03-15 | National Health Coalition, Inc. | Processing Pharmaceutical Prescriptions in Real Time Using a Clinical Analytical Message Data File |
| CN109637613B (en) * | 2018-11-07 | 2022-12-27 | 平安科技(深圳)有限公司 | Method for detecting violation prescription based on data processing and related equipment |
-
2019
- 2019-09-06 TW TW108132337A patent/TWI783172B/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794863B (en) * | 2021-06-02 | 2023-03-01 | 美商醫守科技股份有限公司 | Clinical association evaluating apparatus and clinical association evaluating method |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI783172B (en) | 2022-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200258608A1 (en) | Medical database and system | |
| Hornbrook et al. | Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system | |
| Duru et al. | Mail-order pharmacy use and adherence to diabetes-related medications | |
| US20150248537A1 (en) | Personalized Health Score Generator | |
| US20150356272A1 (en) | Prescription analysis system and method for applying probabilistic model based on medical big data | |
| US10319466B2 (en) | Intelligent filtering of health-related information | |
| Deitelzweig et al. | Health care utilization, costs, and readmission rates associated with hyponatremia | |
| CN113658704A (en) | Diabetes risk prediction device, device and storage medium | |
| Erickson et al. | Adverse medication events related to hospitalization in the United States: a comparison between adults with intellectual and developmental disabilities and those without | |
| US20250114044A1 (en) | Predicting susceptibility of living organisms to medical conditions using machine learning models | |
| CN113724891A (en) | Hospital epidemic situation monitoring method, device and related equipment | |
| US20120253834A1 (en) | Methods, apparatuses and computer program products for facilitating display of relevant quality measures based on diagnoses | |
| TWI783172B (en) | Apparatus and method for processing of a prescription | |
| Pincus et al. | Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care | |
| US20120253842A1 (en) | Methods, apparatuses and computer program products for generating aggregated health care summaries | |
| Comer et al. | Usefulness of pharmacy claims for medication reconciliation in primary care | |
| Getahun et al. | Identifying ectopic pregnancy in a large integrated health care delivery system: Algorithm validation | |
| Lyons et al. | Use of the sentinel system to examine medical product use and outcomes during pregnancy | |
| Chan | Development of a multipurpose dataset to evaluate potential medication errors in ambulatory settings | |
| US20210074397A1 (en) | Apparatus and method for processing of a prescription | |
| US20160019369A1 (en) | System and method for prescribing diagnostic based therapeutics to patients | |
| Shinde et al. | COVID‐19 pregnancy study protocol | |
| TWI895667B (en) | Health management method,device,electronic equipment and storage media | |
| US20240212802A1 (en) | Mapping electronic messages to laboratory result identifiers to inform patient treatment and clinical trial design | |
| Thoegersen et al. | Is a High Medication Risk Score Associated With Increased Risk of 30-Day Readmission? A Population-Based Cohort Study From CROSS-TRACKS |